API-CAT STUDY for APIxaban Cancer Associated Thrombosis
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non
inferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent venous
thromboembolism (VTE) in patients with active cancer who have completed at least 6 months of
anticoagulant therapy for treating a documented index event of proximal deep venous
thrombosis (DVT) (symptomatic or incidental) or pulmonary embolism (symptomatic or
incidental).